The "trial and error" method of choosing excipients has been replaced in 2026 by AI-Assisted Predictive Modeling. Instead of mixing hundreds of combinations in a lab, scientists use digital tools to simulate how a protein will interact with different excipients.
These AI platforms can predict "forced degradation" results with 90% accuracy before a single vial is filled. By 2026, this technology has cut the formulation development phase for new biosimilars from 18 months down to just six. This allows companies to get life-saving treatments to market faster and at a lower cost to the healthcare system.
4 Views